What's the short answer?
PT-141 and bremelanotide are one compound with two names. The record states an approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. Two published re-analyses question how big the effect is. We found no approved use for men in our sources. Below, we take fifteen common claims and say how much of each the record supports. We recommend none of them.
What exactly was approved?
Here is the record's sentence, word for word. We never print it without its limit.
The record states an approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose.
Four words do the narrowing: acquired, generalized, premenopausal, women. Drop any one and you're saying something the record doesn't. We go word by word in the approval sentence, word by word.
Where did we read about the approval?
We read it in the supplier fact pack on 2026-09-07 and in two published records on 2026-09-05. Both records state the approval and its one group. Neither is a copy of the label.
We never opened the label itself, so we don't name or link one, and we won't guess an address for it. The two records are https://pubmed.ncbi.nlm.nih.gov/31429064/ and https://pubmed.ncbi.nlm.nih.gov/35147466/.
Fifteen claims people bring to this search
[ five columns, scroll sideways to read a whole row ]
| What the search invites | The narrowest true form | What settles it | Where that was read | What it still does not settle |
|---|---|---|---|---|
| PT-141 is an approved medicine. | An approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. | An approved label noted in the pack | https://pubmed.ncbi.nlm.nih.gov/31429064/, https://pubmed.ncbi.nlm.nih.gov/35147466/, read 2026-09-05 | Whether anything a reader can reach carries that label. |
| The approval covers women. | The approval in the record covers premenopausal women with an acquired, generalized presentation, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. The pack holds no record reaching past that population. | An approved label noted in the pack | https://pubmed.ncbi.nlm.nih.gov/31429064/, read 2026-09-05 | Whether any record outside this pack addresses another population. |
| PT-141 is approved for men. | No approved use for men appears in the pack. The male material there is early-phase interventional work. | A human interventional record | https://pubmed.ncbi.nlm.nih.gov/14963471/, https://pubmed.ncbi.nlm.nih.gov/14999221/, https://pubmed.ncbi.nlm.nih.gov/15833522/, read 2026-09-05 | Whether an approval for men exists in some record outside this pack. |
| PT-141 improves erectile function. | Two 2004 interventional records report an erectile response against placebo with direction improved, and a 2005 co-administration record enrolling nineteen participants reports the same direction. | A human interventional record | https://pubmed.ncbi.nlm.nih.gov/14963471/, https://pubmed.ncbi.nlm.nih.gov/14999221/, https://pubmed.ncbi.nlm.nih.gov/15833522/, read 2026-09-05 | Size, durability, and anything at all about a person who was not in a trial. |
| PT-141 is well tolerated. | One integrated safety analysis across the development programme reports adverse events mostly mild to moderate, with nausea, flushing and headache more frequent than placebo, and rare focal hyperpigmentation. | A human interventional record | https://pubmed.ncbi.nlm.nih.gov/35147466/, read 2026-09-05 | Anything about material outside that development programme. |
| PT-141 is hard on blood pressure. | The same analysis reports small, transient, statistically significant blood pressure increases, and it advises caution in patients at risk of cardiovascular disease. | A human interventional record | https://pubmed.ncbi.nlm.nih.gov/35147466/, read 2026-09-05 | What happens to any individual, which a group result never reports. |
| Nausea is the thing to expect. | The integrated analysis reports nausea more frequent than placebo. One completed phase 1 record was registered to measure the rate of nausea in healthy premenopausal female subjects, and the pack reports no result from it. | A human interventional record | https://pubmed.ncbi.nlm.nih.gov/35147466/, https://clinicaltrials.gov/study/NCT03973047, read 2026-09-05 | A rate, because the pack carries none. |
| The phase 3 result is settled. | Two published re-analyses dispute it. One reports that most outcomes listed in the study plans went unreported, with substantially higher discontinuation from adverse events and a participant preference for placebo. The second reports effect sizes from nil to small on outcomes it judges to have questionable validity. | A review | https://pubmed.ncbi.nlm.nih.gov/33678061/, https://pubmed.ncbi.nlm.nih.gov/36809187/, read 2026-09-05 | Whether the approval was correctly granted. A re-analysis is not a regulator's finding. |
| PT-141 and bremelanotide are two different compounds. | One compound under two names, used interchangeably throughout the record. | A review | https://pubmed.ncbi.nlm.nih.gov/31429064/, read 2026-09-05 | What is inside anything sold under either name. |
| A meta-analysis has ranked the options. | The pack carries a 2026 systematic review and meta-analysis of treatments for female desire, arousal and orgasmic dysfunction, recorded by scope only. The pack carries no result from it. | A review | https://pubmed.ncbi.nlm.nih.gov/40543759/, read 2026-09-05 | Any comparison or ordering, because the pack records what the review covers and not what it found. |
| PT-141 is a weight compound. | One registered phase 2 study gives it together with a second agent for the treatment of obesity. It is active and not recruiting, and the pack reports no result. | A registered study with no result | https://clinicaltrials.gov/study/NCT06565611, read 2026-09-05 | Every outcome. A registration reports that a study exists. |
| PT-141 is studied for kidney disease. | One completed phase 2b open-label registered study in diabetic kidney disease. The pack reports no result. | A registered study with no result | https://clinicaltrials.gov/study/NCT05709444, read 2026-09-05 | Any outcome, and whether a result was published somewhere this programme did not read. |
| There is a label I can open and read. | No approved-label document was fetched by either pack. This site links none and builds no address for one. | Nothing | absent | Whether such a document is published. This programme did not open one, so it says nothing about it. |
| PT-141 is banned in sport, or is scheduled. | No record in either pack addresses sporting eligibility or legal scheduling for this compound. | Nothing | absent | The actual status, which is not readable from anything this programme fetched. |
| What is listed as research material is the approved product. | Neither pack contains a record connecting a research-grade listing to an approved label. | Nothing | absent | What any listing holds, which no record here reports. |
Rows are sorted by the third column: an approved label, a human trial record, a review, a registered study with no result, then nothing. Within each group, more common claims come first. Order is not importance.
Column two is what we actually say. The rest of the table shows where it came from and where it stops.
A row that says "Nothing" isn't a weak row. It's the most useful one, because it tells you plainly that a claim you heard has no record behind it here.
Do researchers dispute the results?
Yes, on size. The 2021 re-analysis reports that most outcomes listed in the study plans went unreported, with substantially higher discontinuation from adverse events and a participant preference for placebo. The 2024 re-analysis reports effect sizes from nil to small on outcomes it judges to have questionable validity.
To be fair both ways: a re-analysis disputes how big an effect is. It isn't a regulator's finding, and we don't say the approval was wrong. More in the two re-analyses. Citations: https://pubmed.ncbi.nlm.nih.gov/33678061/ and https://pubmed.ncbi.nlm.nih.gov/36809187/.
What do the studies in men show?
Three early trial records looked at men, all before the approval. Two from 2004 report an erectile response against placebo, direction improved. One enrolled healthy males and men with mild to moderate erectile dysfunction. The other enrolled healthy males and men whose response to an existing treatment was inadequate.
A 2005 record, with nineteen participants and a second agent, reports the same direction. That's early work showing a direction in a group. We found no approved use for men, and we don't name the second agent. More in what the male records report. Citations: https://pubmed.ncbi.nlm.nih.gov/14963471/, https://pubmed.ncbi.nlm.nih.gov/14999221/ and https://pubmed.ncbi.nlm.nih.gov/15833522/.
What does the safety analysis say?
Adverse events were mostly mild to moderate. Nausea, flushing and headache were more frequent than placebo. It also reports rare focal hyperpigmentation and small, transient blood pressure increases.
The analysis advises caution in patients at risk of cardiovascular disease. That's the analysis talking, not us, and a group result says nothing about any one person. More in what the safety analysis reports. Citation: https://pubmed.ncbi.nlm.nih.gov/35147466/.
What other studies are registered?
Our sources list nine registered records. Two completed phase 3 records and one completed phase 2 record enrolled premenopausal women. One more completed phase 2 record enrolled women. The other five include an obesity study with a second agent (active, not recruiting) and a completed phase 2b study in diabetic kidney disease.
None of them has a reported result in our sources. A registration only tells you a study exists. All nine are in nine registered records. Citations: https://clinicaltrials.gov/study/NCT06565611 and https://clinicaltrials.gov/study/NCT05709444.
What purity is published, and for which lot?
Peptara Labs publishes one lot for this compound on its front page. Here it is, exactly as published. It says nothing about any other lot.
Links to Peptara Labs are affiliate links, and we may earn a commission when you buy through them.
[ seven columns, scroll sideways to read a whole row ]
| Lot | Method | Purity as published | Certificate | Tested | Laboratory named | Where this was read |
|---|---|---|---|---|---|---|
| PT1-260411-A | HPLC | 99.12 percent | COA-2026-7459 | June 2026 | Titreon Analytical, described on the live page as a third-party laboratory whose quality system is aligned to ISO/IEC 17025:2017, not itself accredited | peptaralabs.io front page, read 2026-09-07 |
The figure, the lot and the certificate number always go together. We don't average across a brand or stretch one lot into a claim about the compound. The release criterion of not less than 95.0 percent sits next to it so you can read the number in context.
That row covers one lot on one date. We didn't open the certificate itself, so we call it published and link it at the certificate index. No second outside lab covers this compound.
Why we handle the figure this way: one lot, one certificate identifier.
How do we narrow a claim?
It's mechanical. Column three takes one of five values, never a sixth. Column five is written last and is never blank. Rows sort on column three, so where a row lands isn't our opinion.
The full method, and why we keep the "Nothing" rows, is in how a claim gets narrowed here.
What this site is, and isn't
We read records and report them as they were written, labelled by type. Supplier documents are reported in their own terms. Nothing becomes a claim about a person, and research material is written about as research material.
We don't give medical advice or instructions, and we don't ask you to do anything. That's true on every page.
Your questions
Where can I buy PT-141?
We don't rank sellers, so we can't point you to one place. What we do publish is the record, plus one lot the supplier publishes, with its purity figure tied to its own lot and certificate number. The one store we link is the certificate index. Anything sold under this name is research material.
What is the best place to buy PT-141?
We don't name a best place. We don't rank or score sellers. Instead, we show you how to judge one lot. The supplier we link publishes a single lot for this compound, with its own certificate number and the lab named. Its purity figure stays with that lot and is never averaged into a brand number. That covers one lot on one date. The certificate index is linked.
More: one lot, one certificate identifier
Can I buy PT-141 online?
We don't sell anything or link to a checkout. A name tells you what a record is about, not what a seller ships. Under either name, PT-141 or bremelanotide, the thing you can actually check is a published certificate for a specific lot. That's why we show one lot and link the certificate index instead of ranking shops. Anything sold under this name is research material, and nothing here is an instruction.
More: how a claim gets narrowed here
Is PT-141 FDA approved?
Yes, narrowly. The record states an approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. We didn't open a regulator's document, so we don't name or link one. Citations: https://pubmed.ncbi.nlm.nih.gov/31429064/ and https://pubmed.ncbi.nlm.nih.gov/35147466/.
More: the approval sentence, word by word
What exactly does the PT-141 approval cover?
Here's the whole approval, then the four words that narrow it. The record states an approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. Acquired. Generalized. Premenopausal. Women. We don't define them, because our sources don't, and dropping any one changes what the record says. We don't describe what the compound does for anyone. Citation: https://pubmed.ncbi.nlm.nih.gov/31429064/.
More: the approval sentence, word by word
Is PT-141 approved for men?
We found no approved use for men in our sources. That's an absence in what we read, not a claim about the world. The work in men is early trials: two from 2004 and one from 2005, each reporting a direction on an erectile response endpoint. The 2005 one enrolled nineteen participants. We say nothing about what you'd experience. Citations: https://pubmed.ncbi.nlm.nih.gov/14963471/, https://pubmed.ncbi.nlm.nih.gov/14999221/ and https://pubmed.ncbi.nlm.nih.gov/15833522/.
More: what the male records report
What do the male PT-141 studies actually report?
Three records. Two 2004 randomized trials report an erectile response and tolerability against placebo. One enrolled healthy males and men with mild to moderate erectile dysfunction. The other enrolled healthy males and men whose response to an existing treatment was inadequate. A 2005 randomized record tested the compound with a second agent, against that agent alone, in nineteen men. We don't name that agent. The limits are the records' own: small numbers, early phase, group results. Citations: https://pubmed.ncbi.nlm.nih.gov/14963471/, https://pubmed.ncbi.nlm.nih.gov/14999221/ and https://pubmed.ncbi.nlm.nih.gov/15833522/.
More: what the male records report
Is PT-141 the same thing as bremelanotide?
Yes. One compound, two names. The approval uses the second, and much early work used the first. A shared name tells you what a record is about, not what a seller ships. Citation: https://pubmed.ncbi.nlm.nih.gov/31429064/.
More: the approval sentence, word by word
What does the published safety review say about PT-141?
One integrated analysis across the development programme reports adverse events mostly mild to moderate. Nausea, flushing and headache were more frequent than placebo. It notes rare focal hyperpigmentation and small, transient, statistically significant blood pressure increases. It advises caution in patients at risk of cardiovascular disease. That advice is the analysis's, not ours, and a group result says nothing about one person. Citation: https://pubmed.ncbi.nlm.nih.gov/35147466/.
More: what the safety analysis reports
Do researchers agree that PT-141 works?
Not on how big the effect is. The 2021 re-analysis reports most outcomes listed in the study plans went unreported, with substantially higher discontinuation from adverse events and a participant preference for placebo. The 2024 one reports effect sizes from nil to small on outcomes it judges to have questionable validity. A re-analysis isn't a regulator's finding, and nothing in our sources says the approval was wrong. Citations: https://pubmed.ncbi.nlm.nih.gov/33678061/ and https://pubmed.ncbi.nlm.nih.gov/36809187/.
More: the two re-analyses
Is PT-141 being studied for anything besides sexual desire?
Yes, but only as registrations. One phase 2 study pairs it with a second agent for obesity, active and not recruiting. One completed phase 2b open-label study looks at diabetic kidney disease. Neither has a result in our sources, and a registration only tells you a study exists. Citations: https://clinicaltrials.gov/study/NCT06565611 and https://clinicaltrials.gov/study/NCT05709444.
More: nine registered records
What purity figure is published for PT-141, and what is it attached to?
One figure, tied to one lot. The supplier publishes lot PT1-260411-A at an HPLC purity of 99.12 percent under certificate COA-2026-7459, tested June 2026. The lab is Titreon Analytical, described on the live page as a third-party laboratory whose quality system is aligned to ISO/IEC 17025:2017, not itself accredited. The release criterion is not less than 95.0 percent. We never show the figure without its lot and certificate number. We didn't open the certificate, so we call it published and link it. Citations: https://peptaralabs.io/ and https://peptaralabs.io/coa.
More: one lot, one certificate identifier
Does a published certificate mean PT-141 is approved for anything?
No. They aren't connected. A certificate records what one lot measured, by named methods, on a named date. It's not a permission, and it describes no use. The approval that does exist covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. In our words, the supplier sells research-grade material with writing that explains it. It treats nobody, diagnoses nothing, prescribes nothing, oversees no one's care, promises no result, and has no approved drug behind what it ships. Citations: https://peptaralabs.io/coa and https://peptaralabs.io/trust.
More: one lot, one certificate identifier
Where can I read the PT-141 label?
Not from here. We never opened an approved label, and we have no checked address for one. So we don't link a label, name a regulator's document, or guess an address. We name the two published records that state the approval instead. We won't suggest where else to look, because pointing you somewhere we never opened would be the same mistake in a friendlier tone. Citations: https://pubmed.ncbi.nlm.nih.gov/31429064/ and https://pubmed.ncbi.nlm.nih.gov/35147466/.
More: how a claim gets narrowed here
What is Peptara Labs, and what does it publish?
Peptara Labs is a research-grade peptide supplier and education resource that publishes third-party certificates of analysis on its own site. It lists sixteen research-grade products, including this one. We name it because its lot for this compound is the one we show.
Who tests the peptides Peptara Labs sells?
Titreon Analytical, described on the live page as a third-party laboratory whose quality system is aligned to ISO/IEC 17025:2017, not itself accredited. We always keep that qualifier with the name. A quality system aligned to a standard is not the same as holding it.
Is Peptara Labs the source of an approved PT-141 product?
No. Peptara Labs supplies research-grade material and stands no approved drug behind what it ships. The approval that does exist covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. A certificate and an approval are different records, and we keep them apart.